Anatomical Background: Autonomic Innervation of the Heart

The autonomous innervation of the heart is based on a complex interaction of central and peripheral mechanisms in sympathetic and parasympathetic parts of the autonomic nervous system (▶Fig. 1). An extrinsic cardiac innervation is distinguished from an intrinsic one.

Extrinsic system

To put it simply, a center of the efferent parasympathetic innervation of the heart is found in the nucleus of the medulla oblongata, especially in the nucleus dorsalis [1]. The preganglionic fibers leave the central nervous system along with the vagus nerve and are connected to the second neuron in cardiac ganglion cells. Sympathetic fibers, on the other hand, originate from the nucleus intermediolateralis of the upper thoracic cord [2]. They reach the plexus cardiacus by means of the so-called "cardiac nerves" (usually 4 right-sided and 3 left-sided nervi cardiaci), after interposition in the border ganglia, especially in the ganglion stellatum. For the control of cardiac functions, the profound part of the plexus cardiacus is decisive; it extends between the tracheal bifurcation and the aortic arch, divides into a right and left half and in its further course follows the right or left coronary artery. The function of the efferent limb is modified by afferents from various organ systems, including the gastrointestinal tract or the carotissinus, by means of multisynaptic reflex arcs (e.g., baroreflex) [1]. In addition, in the blood circulating catecholamine, the release of which in the adrenal system is also subject to the autonomic system, mediates beta-adrenergic effects on the myocardium. It is postulated that dysbalances in the extrinsic system, in particular the pathological disinhibition of sympathetic activity, are relevant to the development of cardiac arrhythmias [1, 3–5]. For example, extensive brain stem damage can lead to suppression of central parasympathetic functions and overcoming of sympathetic tone [6], thus promoting the occurrence of cardiac arrhythmias. Conversely, blockade of the ganglion stellatum or renal sympathetic denervation should reduce the risk of ventricular arrhythmias in patients with prolonged-QT syndromes [7]. It is noteworthy in this context that extensive cardiac denervation, which may be present after orthotopic heart transplantation, is associated with a lower risk of supraventricular rhythm disturbances, especially atrial fibrillation [8]. In these cases, the denervation should have protective effects and protect the myocardium from the autonomic imbalances of the extrinsic system before transmission. It should be noted, however, that organ donors are usually much younger and the vascular damage to the donor organs is often less pronounced, which significantly reduces the risk of atrial fibrillation independent of cardiac denervation [9].
Intrinsic system

The intrinsic system of the cardiac innervation involves a differentiated network of up to 94,000 neurons in approximately 1,000 epicardial ganglions, which are closely connected to the extrinsic system and are divided into 3 anatomically defined groups (retrotriotrial, annulo-ventricular and aorto-pulmonary group) [10]. These neurons use various neurotransmitters, including bradykinin, nitric oxide, neuropeptide Y, CGRP and substance P, the functional significance of which is still unclear. A comparatively dense network of nerve endings is found particularly at the insertion the pulmonary veins in the left atrium, where it is associated with the development of atrial fibrillation [10]. In addition to the electrical isolation of the pulmonary vein opening from the atrial myocardium, initial clinical data indicate that the targeted ablation of autonomc ganglia could also exert an antiarrhythmic effect [11]. However, the identification of suitable epicardial ganglions and their selective ablation is technically sophisticated and currently has only limited clinical application.

Superordinate cortical regulation

More than 100 years ago, the presence of hemispheric regulatory mechanisms upstream to the autonomic centers of the brain stem and the hypothalamus was postulated [12]. This assumption resulted from the simple observation that many vegetative functions, including the increase in blood pressure and heart rate, began well before the beginning of an arbitrary movement to ensure a stable circulation. Underpinned by animal experimental studies and functional imaging, the mesofrontal and insular regions have been considered to be of particular importance for these functions [13–16]. Inactivation (e.g., by ischemic lesions) as well as stimulation of these regions (e.g., epileptic seizures) may lead to central autonomic dysregulations [3]. In a study of patients with acute ischemic stroke and clinically relevant cardiac arrhythmia, the cerebral lesion pattern was more precisely characterized by voxel-based analysis [17]. Similar to earlier investigations, a "hotspot" was found in the insula region of the right hemisphere, which additionally underlines their importance for central autonomic regulation. Further significant associations were found with right frontal and right parietal cortex regions, the right amygdala, basal ganglia and thalamus.

Bradycardic Arrhythmia

In an observational study of 501 patients with acute stroke (92 % ischemic, 8 % hemorrhagic) in a stroke unit (patients with indication for mechanical ventilation were excluded), bradycardic cardiac arrhythmias occurred in the first 3 days after admission in 42 patients (8.4 %) on [18] (Fig. 2). These included 24 cases of atrial fibrillation with bradycardia (ventricular rate < 30/min for at least 30 s or pauses > 3 s), 10 cases with high grade AV block, and 8 cases...
with asystole/sinus arrest. One patient needed cardiopulmonal re-suscitation. In 11 patients, the implantation of a heart pacemaker was necessary. In 21 patients, changes were made in drug therapy (e.g., therapy with β-adrenoceptor blockers was stopped). In earlier studies on this subject, the incidence of bradycardic arrhythmias was significantly lower. Thus, Rem and colleagues reported relevant bradycardia in only 3.2% of patients during 48-h monitoring [19]. The duration and individual technical design of the monitoring is important for the sensitivity of the method, and monitoring the time that elapsed from the beginning of the symptoms is also important. Already in the ECG at admission, prolongation of the PQ interval or a bundle branch block morphology can be seen in more than 50% of patients (Bobinger T. et al., Manuscript in preparation). Interestingly, in a recent meta-analysis of 8 studies with several thousand patients, a significant correlation between PR interval prolongation and the risk of developing atrial fibrillation was observed (RR 1.45, 95% CI 1.23–1.71) [20]. In this context, however, it should be borne in mind that an extension of the atrioventricular conduction in the 12-lead ECG can also be an expression of a drug therapy and about 30% of patients with acute stroke take antiarrhythmic drugs, most often a β-adrenoceptor blocker [18]. In the study mentioned above, most bradycardias were observed immediately during the first 12 h with a rapidly decreasing incidence until the third day after admission [18]. Future studies can use the new options for cardiac long-term monitoring to gain more accurate information on the risk of bradycardia in the medium and long term follow up, especially during the critical phase of physical exercise in neurorehabilitation.

**Tachycardic Arrhythmias**

Tachycardic arrhythmias are significantly more common in the acute phase after stroke than bradycardic ones [18]. Most of the cases are supraventricular tachycardias, usually atrial fibrillation with a tachycardic transition. Ventricular arrhythmias, on the other hand, are particularly important for the long-term course after stroke, as they are the leading cause of the sudden cardiac death [3, 5]. In an American study (Northern Manhattan Study NOMAS [21]), out of 655 patients who had suffered an ischemic stroke for the first time, 37.3% had died within 5 years. In 44 patients, there was primary cardiac death, including most frequently sudden cardiac death, followed by fatal myocardial infarction and terminal heart failure. While the insular cortex is recognized as a vulnerable center of autonomic regulation [3], an association of fatal cardiac complications with infarcts of the parietal lobes was found unexpectedly in the NOMAS study, especially in the left hemisphere. An inhibitory influence of these parietal regions on the insular cortex, which breaks away after ischemic injury and thus causes a sympathetic disinhibition, was proposed as a model [22]. On the cellular level, it is assumed that an unphysiologically high probability of open calcium channel occurs due to the overwhelming activation of β-adrenoceptors by the increased release of cAMP [23–25]. The increased intracellular calcium concentration in turn causes a metabolic imbalance and a myocardial relaxation disorder leading up to cell death and myocyteolysis. Furthermore, the increased sympathetic tone may cause electrolyte disturbances in the serum, in particular hypokalemia and hypomagnesemia, which in turn favor the occurrence of arrhythmias [25]. A prolongation of the QT time is already evident in the 12-lead ECG as a sign of an increased risk of ventricular arrhythmia in a significant section of the patients [26]. According to our own investigations of a cohort with 1141 patients,
Table 1  Selection of studies on atrial fibrillation detection after stroke.

<table>
<thead>
<tr>
<th>Method, Duration</th>
<th>Patient number</th>
<th>Detection rate</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telemetry 24 h</td>
<td>N = 281</td>
<td>4.6 %</td>
<td>Gruber et al., 2012</td>
</tr>
<tr>
<td>Telemetry with review of data 72 h</td>
<td>N = 245</td>
<td>7.3 %</td>
<td>Kallmünzer et al., 2012</td>
</tr>
<tr>
<td>Holter ECG 24 h</td>
<td>N = 120</td>
<td>2.5 %</td>
<td>Rizos et al., 2010</td>
</tr>
<tr>
<td>Holter-ECG 3 Tage</td>
<td>N = 1135</td>
<td>4.3 %</td>
<td>Grond et al., 2013</td>
</tr>
<tr>
<td>Holter ECG 7 Days</td>
<td>N = 220</td>
<td>12.7 %</td>
<td>Stahrenberg et al., 2010</td>
</tr>
<tr>
<td>External event recorder 90 Days</td>
<td>N = 280</td>
<td>16.1 %</td>
<td>Gladstone et al., 2014</td>
</tr>
<tr>
<td>Implantable event recorder 6 Months</td>
<td>N = 221</td>
<td>8.9 %</td>
<td>Sanna et al., 2014</td>
</tr>
</tbody>
</table>

For all studies, only atrial fibrillation episodes of at least 30 s duration have been considered. For comparison: In a meta-analysis of 32 studies, the mean detection rate was 11.5 % (95 % CI: 8.9–14.3 %) [66].

Atrial Fibrillation

Frequency of ischemic stroke

While older studies reported atrial fibrillation in about 20 % of all strokes, the frequency is actually much higher according to recent studies. A cross-sectional study from Sweden reported 33.4 % of a total of 94 083 patients with an ischemic stroke between 2005 and 2010 suffered from atrial fibrillation [29]. It was repeatedly shown that up to 20 % of patients with a stroke who were initially classified as “cryptogenic” had an unidentified, paroxysmal atrial fibrillation.

In view of the great therapeutic relevance, this observation is the starting point for an intensification of the rhythmological diagnosis in stroke patients, which includes both the acute phase in the stroke unit and after discharge into ambulatory care (Table 1).

Emboli in atrial fibrillation: complex pathophysiology

The Framingham Heart Study has shown that clinically manifest atrial fibrillation multiplies the risk of stroke by a factor of 5, independent of other risk factors [30]. However, the underlying mechanisms are still insufficiently understood. Up to now, the stasis of blood flow in the left atrium has been postulated as the cause of embolic complications during the atrial fibrillation episodes [31], in analogy to the Virchow triad. This, in turn, is a direct consequence of a disturbed atrial contraction and atrial dilatation. This approach appears to be intuitively correct but fails to convince as far an understanding of the large number of atrial fibrillation-associated stroke events is concerned. Most recently, newer data have raised serious questions about this approach [32–34]: In the ASERT study, involving 2 580 patients with implanted cardiac pacemaker or AICD aggregate groups, a total of 51 patients during follow-up of 2.5 years suffered an ischemic stroke or a systemic embolism. A reading of the pacemaker memory allowed to study the temporal relationship between atrial fibrillation episodes and the occurrence of stroke: In a period of 30 days before the occurrence of stroke, atrial fibrillation episodes > 6 min were detectable in only n 8 % of the cases. Much more frequently, the episodes occurred more than 30 days earlier, or occurred for the first time after a stroke [32].

Two further studies with similar methodologies also concluded that the majority of cardiac embolisms occur without immediately preceding episodes of atrial fibrillation [33, 34]. Modern concepts are therefore based on the assumption that episodes of atrial fibrillation are only “the tip of the iceberg” and the epiphenomena of a complex disease of the atria, with risk of stroke persisting even after conversion to sinus rhythm [35, 36]. This would also explain why studies on rhythmization have so far yielded essentially no positive results with regard to embolism risk. The center of this atrial disease is possibly atrial fibrosis, which can be demonstrated by sequences showing late gadolinium enhancements in MRI and which, favored by prothrombotic triggers, predisposes to intracardiac thrombus formation [35].

In addition to changes in the plasmatic blood clotting (for instance, increased concentration of prothrombin fragments, D-dimers and increased expression of the von Willebrand factor), inflammatory processes (for example, increased interleukin 6, hs-CRP, various growth factors) are also considered as possible triggers.

Atrial fibrillation and stroke: cause or also consequence?

The autonomic nervous system plays a key role in the pathophysiology of atrial fibrillation [37], which can be seen from the episodic fluctuations in the occurrence of paroxysmal atrial fibrillation. The highest risk is therefore to be found in the early morning and late evening as well as in the winter months [38]. On Saturdays, on the other hand, there are probably fewer episodes of atrial fibrillation than on weekdays. These observations suggest that autonomic imbalances may favor and may even be the cause of the first occurrence of atrial fibrillation [39]. It has been shown that patients with ischemic stroke are significantly more likely to have the first onset of atrial fibrillation episode in the first few hours after the start of neurological symptoms, when the insular cortex region as the center of the autonomic control suffers an injury [40]. It is reported that these patients lack the characteristic features which indicate a high cardiac embolism risk (e.g., proof of intracardiac thrombi or atrial dilatation) [41]. However, this could not be con-
firmed by a recently published work on this subject [42]. It is also possible that the systemic inflammatory reaction associated with the ischemic brain damage is a trigger for the occurrence of atrial fibrillation [43]. However, since there are currently no reliable strategies to determine whether atrial fibrillation is a cause or a possible complication of a stroke, and it is not known whether the embolism risk of the 2 forms differ from each other, these considerations do not yet play a role in the indication for antithrombotic therapy. Patients should initiate oral anticoagulation as secondary prophylaxis of stroke if there are no urgent contraindications [44].

Methods for Arrhythmia Detection

In the methodology for the arrhythmia detection in stroke patients, a distinction must be made between inpatient treatment in a stroke unit and the time after discharge from the hospital.

In the stroke unit

As approximately 3-quarters of all relevant arrhythmias of the acute phase occur within the first 24 h, monitoring is most effective on the first day [18]. In particular, patients with relevant neurological deficits should be monitored for at least 72 h, especially as the severity of stroke is also an independent predictor of cardiac arrhythmias [18]. Monitoring has 2 objectives: 1. Immediate detection of severe, hemodynamically relevant tachycardic and bradycardic arrhythmias; and 2. detection of asymptomatic arrhythmias with significance for secondary prophylaxis, in particular, detection of subclinical episodes of paroxysmal atrial fibrillation. For the first point, the systems operate with acoustic alarm signals, which can be individually activated or deactivated and whose threshold values are to be adjusted in detail. In addition to the experiences of intensive care units in internal medicine departments, for Stroke Unit it could be shown that a too liberal definition of these threshold values contributes to so-called “alarm fatigue” of the staff [45]. Monitoring of stroke patients with cognitive deficits or psychomotor restlessness often produces artifacts, that in a clinical study led to false alarms in over 90% of the arrhythmias detected by the system as suspected life-threatening episodes. It is proposed to define the threshold values for acoustic signals narrowly, thus limiting alarms to vital threats. In addition, a manual evaluation of all detected episodes is necessary regardless of acoustic alarms. For the detection of asymptomatic episodes of atrial fibrillation, continuous monitoring is significantly superior to the serial preparation of 12-lead ECG leads as well as the processing of 24-h Holter ECGs [46, 47]. In order to increase the sensitivity of monitoring, it is useful to systematically analyze the data obtained. There are 2 approaches: 1. In the manual procedure, the ECG lead information is stored on a hard disk and evaluated on site at 24-h intervals similar to the assessment of a long-term ECG. (Fig. 3) An important component of this approach is the preparation of frequency profiles, which allow an immediate identification of suspicious episodes by means of frequency jumps or changes in the frequency band [47]. This simple tool is included in the software of most monitoring systems at no extra cost. The evaluation in the form of a “rhythm visit” takes only a few minutes per patient and can double the sensitivity of the monitoring for the detection of paroxysmal atrial fibrillation [47].

2. In the case of an automated procedure, on the other hand, the raw data are derived from the monitoring system and are sent to a company which carries out the evaluation commercially and makes the results of its evaluation available to the clinic in its reports [46]. The evaluation is based on an automatic analysis of RR interval changes, but the exact functioning of the detection algorithm is a operating secret of the commercial provider. In a clinical study, however, the automatic evaluation increased the sensitivity of the monitoring, but there were 14 false-positive results and 3 false-negative findings among 496 patients [46].

After discharge from the hospital

It is estimated that around 20% of patients with cryptogenic stroke suffer from unrecognized paroxysmal atrial fibrillation. This is the starting point for an intensification of ECG monitoring beyond treatment in a stroke unit. Regular clinical examination, the patient manually checking his own pulse and processing of Holter ECG data are proposed as useful basic measures for the follow-up of these patients [48]. The pulse checked by the patient represents a simple screening instrument with few false-positive results, which can be reliably learned by the majority of stroke patients. For selected patient groups, external or implantable event recorders are available that allow continuous monitoring of cardiac rhythm over several years [49, 50]: In the CRYSTAL-AF study, 441 patients who had suffered an ischemic stroke within 60 days prior to study inclusion were randomized either to receive an implantable event recorder (Medtronic® Reveal XT) or standard treatment. After 6 months, with the help of the event recorder, a significantly greater number of patients with paroxysmal atrial fibrillation could be detected (HR 6.4, 95% CI: 1.9–21.7). However, it should be noted that only 88 resting ECGs and 20 Holter ECGs were performed in the control group with n = 220 patients, which according to today’s standard does not correspond to an adequate follow-up program for patients with cryptogenic stroke. The difference to the implantable event recorders should therefore be relativized if patients receive a close, non-invasive follow-up.

Therapy

Basic measures

The first-time occurrence of cardiac arrhythmias in stroke patients represents an emergency with a potentially vital threat. The important aspects of management are summarized in Table 2. In the case of hemodynamically relevant disorders, the procedure is according to the emergency medical recommendations for on-call resuscitation team [51]. In the case of tachycardias, an emergency cardioversion may be considered, in the case of bradycardia, the beginning of a transcatheterous pacemaker stimulation or the placement of a temporary pacemaker. In the case of disturbances without immediate hemodynamic relevance, cardiorespiratory monitoring of the vital parameters, physical examination (volume status, cervical congestion, pulse deficit, auscultation), a 12-channel ECG and a laboratory-chemical diagnostics (electrolytes, blood count, renal function, myocardial marker, TSH) should be carried out. Underlying diseases that need treatment (e. g., acute myocardial infarction, aortic dissection or increase in intracranial pressure, recurring stroke) as a cause of arrhythmia must be excluded. Potentially proarrhythmogenic conditions must also be recorded and
treated (volume deficiency, electrolyte disturbances, infections, fever, hypothermia, hyperthyroidism, etc.).

**Specific antiarrhythmic therapy**

Close cooperation between the neurologist and the cardiologist is of great importance for the selection of the optimal antiarrhythmic therapy; in particular, echocardiography is usually indispensable in this context. In deciding upon therapy, not only the severity and extent of neurological deficits of the patient, but also the exact nature of the arrhythmia, underlying cardiac diseases, renal function and any concomitant medication must be taken into account. In the clinical routine of a stroke unit, antiarrhythmic management is most frequently encountered in tachycardic atrial fibrillation. The current ESC recommendations for this indication are summarized in **Table 3** [44]. Accordingly, for controlling the frequency of atrial fibrillation in patients with no clinical signs of cardiac insufficiency and with a left ventricular ejection fraction of >40%, either β-adrenoceptor blockers or calcium antagonists are considered as first-line drug therapy. The first target should be a resting heart rate <110/min. If this is not possible, the start of cardiac glycosides should also be considered.

In patients with reduced left ventricular function or signs of cardiac insufficiency calcium antagonist, have to be avoided and the dosage of the beta-blocker should be carried out with great care. Amiodarone is an effective alternative, but is used with caution due to the spectrum of its side effects [44]. In the long term, frequency-regulating therapies for thrombembolic complications and mortality are not inferior to cardiac rhythm maintaining procedures. Only when the cardiological indication is confirmed (for instance, sustained clinical symptoms despite good frequency control),

<table>
<thead>
<tr>
<th>Priority</th>
<th>Key question</th>
<th>Clinical examples</th>
<th>Important measures (Choice)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Is there acute cardiac insufficiency?</td>
<td><strong>Low-Output:</strong> Blood pressure drop, shock, syncope. <strong>Backward heart failure:</strong> Lung edema, peripheral edema.</td>
<td><strong>Bradyarrhythmias:</strong> Stop medications causing bradyarrhythmias, if necessary temporary pacemaker stimulation, initially mostly transcutaneously (40–200 mA, impulse breadth 20–40 ms, 70/Min), atropine 0.5–1.0 mg i. v. (caution: conduction block below the AV node often atropine resistant). Orciprenaline 0.25–0.5 mg i. v. (off-label), adrenaline 0.01 mg i.v. Tachycardias: in ventricular arrhythmias if needed emergency cardioversion (biphasic 120–360 J or 360 J monophasic), amiodarone 300 mg i. v. over 5 min in glucose 5%. In supraventricular or junctional tachycardias frequency control with medication depending on the individual case (cf. Tabelle 3),</td>
</tr>
<tr>
<td>2.</td>
<td>Is there an underlying acute illness needing treatment?</td>
<td>Cerebral: ICP rise (usually bradyarrhythmias), recurrent infarction, secondary cerebral hemorrhage, cerebral vasospasm. Cardiac: Acute myocardial infarction, aortic dissection, myocarditis Others: Acute kidney failure, sepsis</td>
<td>Laboratory parameters (especially electrolytes, renal function, blood count, CRP, TSH). If necessary, exclusion of acute myocardial ischemia, coronary diagnosis, CT angiography (dissection?) If necessary, cerebral imaging (CCT), specific therapy depending on the findings (e.g., reduction of ICP, ventricular drainage, etc.).</td>
</tr>
<tr>
<td>3.</td>
<td>Are there predisposing factors?</td>
<td>Volume deficiency Electrolyte disorders (hypokalemia, hypomagnesia), infections, fever, hypothermia, hyperthyroidism.</td>
<td>Possibly Volume substitution, parenteral compensation of hypokalemia Magnesium substitution (8 mmol Mg2 + in 100 ml over 60 min.). Search for locus of infection, if necessary antibiotic therapy, targeted temperature management.</td>
</tr>
<tr>
<td>4.</td>
<td>Is there an indication for anticoagulation?</td>
<td>Atrial fibrillation Atrial flutter</td>
<td>Determination of thromboembolic risk (for non-valvular AF, for example by means of CHA2DS2Vasc score) and bleeding risk (e. g., HAS-BLED score). Determination of renal function. (Specific relevance: age, size of the cerebral infarction, concomitant medication, cognitive deficits, renal/hepatic impairment, gastrointestinal disorders, previous bleeding, etc.).</td>
</tr>
<tr>
<td>5.</td>
<td>Is there an indication for specific antiarrhythmic therapy?</td>
<td>Frequency-stabilizing vs. rhythm-conserving strategy, ablation techniques for atrial fibrillation, AV-junctional arrhythmias, or symptomatic atrial fibrillation. Supply with AICD or pacemaker.</td>
<td>Echocardiography, internistic co-assessment. Further diagnosis depends on the individual case. In many patients with stroke and atrial fibrillation, a drug-stabilizing therapy is sufficient.</td>
</tr>
<tr>
<td>6.</td>
<td>Is there an autonomous dysregulation?</td>
<td>Sympathetic disinhibition; Autonomic neuropathy</td>
<td>Measurement of heart rate variability at rest and under provocation (for example, Valsalva maneuver, metronomical breathing), if appropriate indication for cardiac long-term monitoring, causal clarification and treatment of autonomic neuropathy.</td>
</tr>
</tbody>
</table>
rhythm-conserving procedures should be considered with permanent, adequate oral anticoagulation in stroke patients. For this specific indication, dronedarone is recommended [44]. In case the drug therapy fails, in the long term, invasive procedures are also used, for example, implantation of a pacemaker in combination with ablation of the AV node.

**Antithrombotic therapy**

After ischemic stroke and nonvalvular atrial fibrillation, oral anticoagulation is indicated for secondary prevention. The same recommendation applies to patients with atrial fibrillation, who can be assumed to have a comparably high risk of thrombembolism [52]. In addition to the vitamin K antagonists, 4 preparations are currently available from the group of non-vitamin K antagonist anticoagulants (NOAC) (Table 4), including the direct thrombin inhibitor dabigatran as well as 3 factor Xa antagonists (rivaroxaban, apixaban, edoxaban). A meta-analysis of data on patients from clinical studies treated in the context of secondary prophylaxis of stroke has shown a superior benefit-risk ratio of NOAC as against warfarin [53]. A recent retrospective study of 118891 patients over the age of 65 indicated that intracerebral and extracranial bleeding occur more frequently among those treated with rivaroxaban compared to dabigatran [54]. However, prospective data on this subject are not available, which is why the selection of the drug has to be based on the specific features of individual patients (in particular, age, renal function, liver function, pre-existing diseases, concomitant medication, compliance, etc.) [55, 56]. A particularly critical question is the optimal time for the start of the treatment after stroke: If treatment is delayed, the patient is unprotected and exposed to a high risk of recurrence, but if the patient is anticoagulated too early, it could increase the risk of bleeding complications, or complicate acute management (e.g., hemicraniectomy in the case of a cerebral infarction). On the other hand, it is assumed that the secondary prophylactic benefit of NOAC is greatest in the peracute phase. The NOAC clinical studies do not provide any information on these issues since patients were excluded in the first few weeks after stroke due to safety concerns. For heparins in therapeutic doses, on the other hand, a high risk of bleeding is known.

**Table 3** Frequency control according to recommendations of ESC [44].

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Acute intravenous Dosage</th>
<th>Long-term oral Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta-adrenozeptor blocker</td>
<td></td>
<td></td>
<td>Side effect: Bradycardias, hypotension, AV block, bronchospasm.</td>
</tr>
<tr>
<td>Metoprolol</td>
<td>2.5–10 mg bolus</td>
<td>Up to 97.5 mg 2x/d</td>
<td>Side effect: Bradycardias, hypotension, AV block, bronchospasm.</td>
</tr>
<tr>
<td>Esmolol</td>
<td>0.5 mg bolus, then 0.05–0.25 mg/kg/min</td>
<td></td>
<td>Contraindication: LVEF &lt; 40 %. Relative: Combination with beta blocker.</td>
</tr>
<tr>
<td>Calcium channel antagonists</td>
<td></td>
<td></td>
<td>Side effect: Bradycardia, hypotonia, flush, headache.</td>
</tr>
<tr>
<td>Verapamil</td>
<td>2.5–10 mg bolus</td>
<td>Up to 120 mg 3x/d</td>
<td>High serum levels proarrhythmogenic and associated with higher mortality. Caution: Hypokalemia. contraindication: access. conduction pathway ventricular, arrhythmias. Control of renal and liver function necessary.</td>
</tr>
<tr>
<td>Diltiazem</td>
<td>15–25 mg bolus</td>
<td>Up to 120 mg 3x/d</td>
<td></td>
</tr>
<tr>
<td>Cardiac glycoside</td>
<td></td>
<td></td>
<td>In case of failure, other measures. Side effect: QT-prolongation, lung fibrosis, thyroid dysfunction, cataract, skin changes.</td>
</tr>
<tr>
<td>Digoxin</td>
<td>0.5 mg bolus, up to 3x/24 h</td>
<td>Control levels, mostly 0.1 mg/d</td>
<td></td>
</tr>
<tr>
<td>Digitoxin</td>
<td>0.4–0.6 mg bolus</td>
<td>Control levels 0.05–0.3 mg/d</td>
<td></td>
</tr>
<tr>
<td>Special indication</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td>300 mg in 5 % glucose</td>
<td>200 mg/d</td>
<td></td>
</tr>
</tbody>
</table>

**Table 4** Non-vitamin-K-antagonistic oral anticoagulants in non-valvular atrial fibrillation.

<table>
<thead>
<tr>
<th>Substance</th>
<th>Standard dose</th>
<th>Reduced dose</th>
<th>Criteria for dose reduction (choose)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dabigatran (Pradaxa®)</td>
<td>2 × 150 mg/d or 2 × 110 mg/d</td>
<td>2 × 110 mg/d</td>
<td>Concomitant medication with verapamil, age &gt; 80 years. Optionally in cases of increased risk of bleeding, age &gt; 75 years, creatinine clearance &lt; 50 ml/min, GI disorders.</td>
</tr>
<tr>
<td>Rivaroxaban (Xarelto®)</td>
<td>1 × 20 mg/d</td>
<td>1 × 15 mg/d</td>
<td>Creatinine clearance &lt; 50 ml/min</td>
</tr>
<tr>
<td>Apixaban (Eliquis®)</td>
<td>2 × 5 mg/d</td>
<td>2 × 2.5 mg/d</td>
<td>Creatinine clearance &lt; 15–29 ml/min Alternative when 2 from 3 met: Age ≥ 80 years BW ≤ 60 kg or serum creatinine ≥ 1.5 mg/dl.</td>
</tr>
<tr>
<td>Edoxaban (Lixiana®)</td>
<td>1 × 60 mg/d</td>
<td>1 × 30 mg/d</td>
<td>Creatinine clearance &lt; 50 ml/min or BW ≤ 60 kg or treatment with (P-gp) inhibitors</td>
</tr>
</tbody>
</table>
from previous studies in acute stroke, which is why these rare high-risk constellations remain under strict risk-benefit assessment (e.g., mechanical valve prosthesis in mitral position, vessel dissection) [57]. Once intracranial hemorrhage is excluded by imaging studies, the start of oral anticoagulation is currently individualized, taking into account the size of the infarction, clinical condition of the patient, risk of embolism, blood pressure control, concomitant medication and other factors usually between day 1 and day 12 after cardioembolic stroke [44, 58].

“Cryptogenic stroke” and “Embolic stroke of undetermined source” (ESUS)

The concept of “cryptogenic stroke” is not based on a general definition. The frequently cited TOAST criteria (Trial of Org10172 in Acute Stroke Treatment [59]) included both patients without a detectable cause of stroke in addition to patients with incomplete diagnostic evaluation, as well as those with multiple competing causes [60]. In large studies, about one in 4 stroke patients were assigned to this group [60]. It is to be assumed that in many cases an unrecognized cardiac embolic source is present, for example, paroxysmal atrial fibrillation. Already clinical and demographic data can support this assumption, for example, a patient over 62 years of age or with severity of stroke > 8 on the NIHSS without attributing the symptoms to a lacunar syndrome [61]. Biomarkers in the serum, troponin [62] and BNP [63] as well as a dilated left atrium in echocardiography [64] are also associated with cardioembolic genesis, although there is no definite evidence for this. Controversy about the adequate antithrombotic therapy after cryptogenic stroke required the definition of a new entity, the “Embolic Stroke of Undetermined Source, ESUS”. This includes all ischemic, non-lacunar, “embolic” strokes without evidence for a stenosis of the associated vessels supplying the brain, without definitive evidence for a cardiac source of embolism and after exclusion of other causes (e.g., arteritis, dissection, migraine infarction, vasospasm, drug-associated) [65]. Whether oral anticoagulation is beneficial for these patients is currently being investigated in large placebo-controlled clinical trials against a standard therapy with thrombocyte function inhibition. If the study results are positive, a paradigm shift can be expected in antithrombotic therapy after stroke.

Perspectives and Open Questions

In many patients, cardiac long-term monitoring or the readouts of pacemaker activity have frequently detected high-frequency atrial episodes not meeting the criteria of atrial fibrillation. Although there is an increased risk of stroke in this constellation, it is controversial whether this justifies the start of anticoagulation. There are also open questions concerning the optimal management of patients who suffer a stroke under NOAC; in particular, deciding if intravenous thrombolysis is indicated is a particular challenge. Specific antidotes and coagulation tests, provided that they can be made available in an emergency situation, are becoming increasingly important in this context. Autonomic disorders in the stroke patient often remain unnoticed. If in the future it becomes possible to identify autonomic dysfunction already in the acute phase, this would be the first step towards prophylaxis of secondary complications in the long-term course after stroke.

Conflict of interest

No conflict of interest has been declared by the authors.

References


[33] Daoud EG, Glotzer TV, Wyse DG et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm 2011; 8: 1416–1423


[37] Chen PS, Chen LS, Fishbein MC et al. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circul Res 2011; 114: 1500–1515


